Choosing an automated nucleic acid purification system: where an automated nucleic acid extraction system pays for itself, magnetic bead against column chemistry, and the throughput and contamination questions that decide the platform
Automating extraction is bought for consistency as much as for hands-off time: a bead protocol run identically every day removes the operator variance that shows up downstream as unexplained inhibition and variable yield. This page covers when it pays, which chemistry suits which sample, and the questions that separate platforms once the brochures are set aside.
- the deck sizes most extraction platforms are built around
- 24 to 96
- the containment human primary samples are handled at
- BSL-2
- the electronic records rule covering the instrument's run record
- Part 11
Figures in this panel are the deck size conventions these platforms are sold in and the containment and records rules the work is done under, linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply an instrument price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Specifying the platform
- Count the real daily demand, and the shape of it. A platform that processes twenty four samples per run suits a laboratory with a steady flow; one that processes ninety six suits batching. A laboratory whose work arrives as four samples at a time all day will run an expensive instrument at a fraction of its capacity.
- Choose the chemistry from the sample, not the instrument. Magnetic bead chemistry dominates automation because it needs no centrifugation and scales cleanly. Column chemistry gives excellent purity for some difficult samples. Match it to your hardest sample type, because that is the one that will fail.
- Check the validated protocols you actually need. Blood, tissue, swabs, saliva, plant material and stool all behave differently and each needs its own validated protocol. A platform with one generic protocol will need method development for everything else, and that is the hidden cost.
- Take contamination control seriously on a shared deck. An open deck processing amplifiable material next to extraction is a cross contamination risk. Closed cartridges remove most of it at a higher consumable cost. Decide which matters more before the platform is chosen rather than after the first false positive.
- Price the consumables over five years. Cartridges and plates are where the money goes, and they are proprietary on most platforms. A cheap instrument with expensive locked-in consumables is frequently the costlier choice, and the sum is easy to do before purchase.
Validating the transfer from manual to automated
Run the same samples both ways and compare yield, purity ratios, integrity and, most importantly, downstream performance. Yield is the least informative of the four: a preparation with good yield and a co-purifying inhibitor is worse than a smaller clean one.
Keep the manual protocol working and documented. Instruments fail, and a laboratory that has forgotten how to extract by hand stops entirely when it does.
Sample input and what it constrains
Input volume ranges are narrower than they look, and a platform that takes two hundred microlitres of blood will not take two millilitres without a concentration step. Check the range against your real samples, including the awkward ones.
Tube and plate formats have to match what arrives. A platform requiring a proprietary tube adds a transfer step, and every transfer is a chance to mislabel.
Service and downtime
For a laboratory with one platform and a daily workload, the service response time is the specification that matters most. Ask about loan instruments and typical repair turnaround, and get both in the contract.
Where extraction is on a critical path, a second smaller instrument is cheaper insurance than an upgraded service tier, and it doubles as overflow capacity.
Common questions
- When does an automated nucleic acid extraction system pay for itself?
- Usually at a few dozen samples a day, and sooner where consistency rather than hands-off time is the driver. Below that, the consumable premium and the maintenance rarely beat a good manual protocol and a careful operator.
- Magnetic beads or columns?
- Beads for almost all automation, because they need no centrifugation and scale cleanly across deck formats. Columns still win on some difficult matrices where their purity is genuinely better, and a platform that supports both keeps that option open.
- Does automation improve yield?
- Not usually. It improves consistency, which is often the more valuable property: a tighter distribution of yield and purity makes downstream quantification and normalisation far more reliable, even when the mean is unchanged.
- What about cross contamination?
- It is the real risk on an open deck, particularly in a laboratory that also amplifies. Closed cartridge systems, physical separation of pre and post amplification areas, and regular environmental swabbing are the controls that matter.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/automated-nucleic-acid-purification/.